On March 7, 2016 Oxford BioMedica plc ("Oxford BioMedica" or "the Group") (LSE: OXB), a leading gene and cell therapy group, reported a new and expanded collaboration with Immune Design Corp. ("Immune Design"), a clinical-stage immunotherapy company focused in oncology, as well as a non-exclusive, royalty-bearing, intellectual property licence to Immune Design (Press release, Oxford BioMedica, MAR 7, 2016, View Source [SID:1234509399]). Schedule your 30 min Free 1stOncology Demo! The licence involves the use of lentiviral vector-based products for the in vivo treatment or prevention of cancer. The collaboration builds on Immune Design’s earlier process development collaboration with the Group, signed in 2012, which covered the development of analytic assays. Financial and other terms have not been disclosed.
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
John Dawson, Chief Executive Officer of Oxford BioMedica, commented: "We are delighted to sign an IP licence and an expanded collaboration agreement with Immune Design. Oxford BioMedica has world-leading capabilities in lentiviral vector process development and manufacture and these agreements with Immune Design are further evidence of our attractiveness as a partner to other companies and academic institutions working with lentiviral vector based products. I expect that during 2016 we will be able to make further announcements of similar agreements with other parties"